We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00300404
First Posted: March 8, 2006
Last Update Posted: May 22, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Stanley Medical Research Institute
Information provided by:
Zentrum für Integrative Psychiatrie
March 7, 2006
March 8, 2006
May 22, 2006
January 2002
Not Provided
Psychopathology ratings
Same as current
Complete list of historical versions of study NCT00300404 on ClinicalTrials.gov Archive Site
TG infection parameters
Same as current
Not Provided
Not Provided
 
Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study
We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection. As TG modulates neurotransmitter metabolism affecting serotonin and dopamine we hypothesize that this chronic persistent infection might play a role for depressive and psychotic symptomatology. Therefore, on the basis of an ex juvantibus approach, specific anti TG medication might further improve psychiatric symptomatology in affected patients. This is investigated in a double-blind, placebo-controlled, randomized treatment trial.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Schizophrenia
  • Major Depression
  • Drug: daraprim
  • Drug: pyrimethamine
  • Drug: folinic acid
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
September 2005
Not Provided

Inclusion Criteria:

  • Schizophrenia or Major Depression
  • Both genders
  • Adult
  • Patients are able to give informed consent

Exclusion Criteria:

  • Additional diagnosis of substance abuse/dependency
  • Continuous treatment with medication not compatible with study medication
  • Medical status not compatible with study medication
  • Any condition that increases study risk considerably
  • Pregnancy, nursing
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00300404
TOXO-KI-TT
SMRI grant # 01T-404
Not Provided
Not Provided
Not Provided
Not Provided
Zentrum für Integrative Psychiatrie
Stanley Medical Research Institute
Principal Investigator: Dunja Hinze-Selch, MD Zentrum für Integrative Psychiatrie
Zentrum für Integrative Psychiatrie
March 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP